Get started
Author

Viktoriya Stalbovskaya

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
2012 · Claire Harrison, Jean-Jacques Kiladjian, et al. · New England Journal of Medicine · 1,823
PDF
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
2016 · on behalf of the COMFORT-II Investigators, C N Harrison, et al. · Leukemia · 519
PDF
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
2013 · Francisco Cervantes, Alessandro M. Vannucchi, et al. · Blood · 426
PDF
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
2015 · A. M. Vannucchi, H. M. Kantarjian, et al. · Haematologica · 260
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
2025 · Alison M. Schram, Koichi Goto, et al. · New England Journal of Medicine · 140
PDF
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study
2014 · Paola Guglielmelli, Flavia Biamonte, et al. · Blood · 132
Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.
2022 · Alison M. Schram, Koichi Goto, et al. · Journal of Clinical Oncology · 65
Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)
2012 · Francisco Cervantes, Jean-Jacques Kiladjian, et al. · Blood · 57
Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions.
2021 · Alison M. Schram, Eileen Mary O'Reilly, et al. · Journal of Clinical Oncology · 54
Ruxolitinib is an effective treatment for CALR ‐positive patients with myelofibrosis
2015 · Paola Guglielmelli, Giada Rotunno, et al. · British Journal of Haematology · 49
PDF
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
2015 · Mary Frances McMullin, Claire N. Harrison, et al. · Experimental Hematology and Oncology · 44
PDF
Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
2017 · C N Harrison, A M Vannucchi, et al. · Leukemia · 43
PDF
Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis
2016 · Haifa Kathrin Al-Ali, Viktoriya Stalbovskaya, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 40
Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).
2020 · Barbara Pistilli, Hans Wildiers, et al. · Journal of Clinical Oncology · 34
Estimands for overall survival in clinical trials with treatment switching in oncology
2021 · Juliane Manitz, Natalia Kan‐Dobrosky, et al. · Pharmaceutical Statistics · 33
Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs.
2020 · Erika Paige Hamilton, Thierry Petit, et al. · Journal of Clinical Oncology · 31
Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF).
2011 · C. N. Harrison, J. Kiladjian, et al. · Journal of Clinical Oncology · 31
Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT)
2012 · Alessandro M. Vannucchi, Francesco Passamonti, et al. · Blood · 25
Double-blind evaluation and benchmarking of survival models in a multi-centre study
2006 · A. Taktak, L. Antolini, et al. · Computers in Biology and Medicine · 25
Estimand framework: Are we asking the right questions? A case study in the solid tumor setting
2020 · Michelle Casey, Evgeny Degtyarev, et al. · Pharmaceutical Statistics · 24
The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT)
2013 · Matthew Squires, Claire N Harrison, et al. · Blood · 18
ReTHINK: A randomized, double-blind, placebo-controlled, multicenter, phase 3 study of ruxolitinib in early myelofibrosis patients.
2016 · Francesco Passamonti, Jean-Jacques Kiladjian, et al. · Journal of Clinical Oncology · 16
Abstract CT012: Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC)
2023 · Ezra E. Cohen, Jérôme Fayette, et al. · Cancer Research · 14
Expand: a Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis and Baseline Platelet Counts Between 50 × 109/L and 99 × 109/L
2012 · Claire N Harrison, Heinz Gisslinger, et al. · Blood · 13
Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results
2015 · Claire N. Harrison, Alessandro M. Vannucchi, et al. · Blood · 12
Works count: 50
Citation count: 4,019
H-index: 20
I10-index: 26
Year
Topic
Type